ANI Approved for Oxycodone HCl Capsules

Oxycodone HCI has multiple actions qualitatively similar to those of morphine
Oxycodone HCI has multiple actions qualitatively similar to those of morphine

ANI announced that the Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for Oxycodone HCl Capsules.  

Oxycodone HCl is a Schedule II substance indicated for the management of moderate to severe acute and chronic pain where the use of an opioid analgesic is appropriate. Oxycodone HCl is a pure agonist opioid that has multiple actions qualitatively similar to those of morphine. The most prominent of these involves the central nervous system and organs composed of smooth muscle.

RELATED: FDA Announces Major Labeling Changes for Opioids

Oxycodone HCl Capsules will be available in a 5mg strength. 

For more information call (800) 434-1121 or visit AniPharmaceuticals.com.

Loading links....